1:47
EBMT 2016 | Why children should be offered choices in their treatment plans
Imelda Coyne
1:41
EBMT 2016 | Why it is important to involve children and adolescents in treatment decision-making
Imelda Coyne
2:52
EBMT 2016 | The role of proteasome inhibitors in multiple myeloma
Mohamad Mohty
3:11
EBMT 2016 | Information is key: why patients need to be empowered to learn about their disease
John Murray
2:15
EBMT 2016 | Assessment of response in multiple myeloma: next steps
Bruno Paiva
2:27
EBMT 2016 | Highlights from EBMT 2016: Immunotherapy
Arnon Nagler
2:30
EBMT 2016 | FLT3 inhibitors – their role in AML
Ali Bazarbachi
1:34
EBMT 2016 | Next steps for novel treatments in multiple myeloma
Bruno Paiva
2:44
EBMT 2016 | The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini
1:49
EBMT 2016 | Drugs vs transplants in acute leukemias
Arnon Nagler
2:48
EBMT 2016 | Virus-specific T cells – effectiveness, safety profile and use
Ann Leen
1:39
EBMT 2016 | The significance of FLT3 mutations in AML
Ali Bazarbachi
3:35
EBMT 2016 | Assessment of response in MM: challenges and advances
Bruno Paiva
2:30
EBMT 2016 | Matched unrelated donor (MUD) transplantations for ALL and AML
Arnon Nagler
3:22
EBMT 2016 | CAR T-cells and fast cars
Antonio Pagliuca
1:14
EBMT 2016 | ‘Off the shelf’ virus-specific T cells
Ann Leen
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals